News headlines about Medifast (NYSE:MED) have trended somewhat positive on Sunday, according to Accern. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Medifast earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned media coverage about the specialty retailer an impact score of 47.723128482237 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the news headlines that may have impacted Accern’s scoring:

Medifast (NYSE:MED) traded up 2.25% during trading on Friday, hitting $50.87. The stock had a trading volume of 174,473 shares. The stock has a 50 day moving average price of $42.47 and a 200-day moving average price of $43.33. Medifast has a 12 month low of $35.55 and a 12 month high of $51.07. The stock has a market cap of $606.88 million, a price-to-earnings ratio of 25.56 and a beta of 0.48.

Medifast (NYSE:MED) last issued its quarterly earnings results on Tuesday, August 8th. The specialty retailer reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.10. Medifast had a return on equity of 24.25% and a net margin of 8.62%. The firm had revenue of $75.70 million for the quarter, compared to the consensus estimate of $71.96 million. During the same period in the prior year, the business posted $0.63 earnings per share. The company’s revenue for the quarter was up 6.5% on a year-over-year basis. On average, equities analysts predict that Medifast will post $2.12 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 9th. Stockholders of record on Friday, June 23rd were issued a $0.32 dividend. The ex-dividend date was Wednesday, June 21st. This represents a $1.28 annualized dividend and a dividend yield of 2.52%. Medifast’s payout ratio is 64.32%.

Several equities analysts have recently issued reports on the company. BidaskClub raised Medifast from a “strong sell” rating to a “sell” rating in a research note on Friday. Sidoti cut Medifast from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 2nd.

WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/13/medifast-nysemed-receiving-somewhat-positive-news-coverage-accern-reports.html.

Medifast Company Profile

Medifast, Inc is engaged in the production, distribution and sale of weight loss, weight management and healthy living products, and other consumable health and nutritional products. Medifast product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products and vitamins.

Insider Buying and Selling by Quarter for Medifast (NYSE:MED)

Receive News & Ratings for Medifast Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast Inc and related companies with MarketBeat.com's FREE daily email newsletter.